TROG Cancer Research
Members Login   CQMS Login

TROG 08.09 (RTN2)

Primary sponsor: Australia and New Zealand Melanoma Trials Group (ANZMTG)
Collaborating group: Trans Tasman Radiation Oncology Group (TROG)


A trial of postoperative radiation therapy following wide excision of neurotropic melanoma of the head and neck


This trial is suitable for people that have been diagnosed with an unusual form of melanoma known as neurotropic melanoma. Neurotropic melanoma is characterised by the presence of melanoma cells around nerve sheaths or within nerves. When this type of melanoma is diagnosed on the head or neck region the standard treatment is surgery.

This disease may have a high rate of local relapse (recurrence of melanoma in the same area) after surgery. In some hospitals, immediate post-operative radiotherapy is already the standard treatment, but in other hospitals it is not. It is not known for certain whether the benefits of radiotherapy outweigh the risks.

The purpose of this trial is to investigate if having radiation therapy soon after surgery is better at preventing the melanoma recurrence than just having surgery alone.

Participating centres

Current participating centres (PDF)

Accrual target


Current accrual

Current accrual graph (PDF)

Expected date of accrual completion


Trial chairperson

A/Prof Matthew Foote, Princess Alexandra Hospital, QLD

Trial contact

Narelle Williams
Senior Project Officer
Melanoma and Skin Cancer Trials Group Ltd
Phone: +61 414 579 120

Further information

TROG trial 08.09 on Australian Cancer Trials website

Trial resources for TROG members

TROG 08.09 member page

Patient referral flyer - Download PDF

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.